Additionally, molecular imaging enables the accurate selection of patients who are more likely to benefit from PD-1/PD-L1 inhibitors by providing insights into the tumor microenvironment and interactions between the tumor and the immune system. The gene discussed is CD274; the disease is neoplasm.